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Determination of the range in binding-site densities of rat skin
heparin chains with high binding affinities for antithrombin
Alan A. HORNER,* Marion KUSCHE,t Ulf LINDAHLt and Cynthia B. PETERSON:
*Department of Physiology, University of Toronto, Toronto, Ont. M5S 1A8, Canada,
tDepartment of Medical and Physiological Chemistry, Swedish University of Agricultural Sciences, S-751 23 Uppsala,
Sweden, and tDepartment of Biochemistry and Molecular Biology, Louisiana State University Medical Center,
Shreveport, LA 71130, U.S.A.
Rat skin heparin proteoglycans vary markedly in the proportions of their constituent polysaccharide chains
that have high binding affinity for antithrombin. As the proportion of such chains in a proteoglycan rises,
their degree of affinity for antithrombin also increases [Homer (1987) Biochem. J. 244, 693-698]. The
antithrombin-binding-site densities of such chains have now been determined, by measuring heparin-
induced enhancement of the intrinsic fluorescence of antithrombin and by chemical analysis for the
disaccharide sequence glucuronosyl-N-sulphoglucosaminyl (3,6-di-O-sulphate), which is unique to this site
in heparin [Lindahl, Backstrom, Thunberg & Leder (1980) Proc. Natl. Acad. Sci. U.S.A. 77, 6551-6555].
Antithrombin-binding-site density ranged from one to five sites per chain.
INTRODUCTION
It has been demonstrated (Homer, 1987) that heparin
chains with high affinity for antithrombin (HA-chains),
which are components of HA-heparin proteoglycans
from rat skin (Homer & Young, 1982), are very
heterogeneous, with specific anticoagulant activities
covering an approximately 10-fold range. It was postu-
lated, by deductions that involved comparisons with
published data obtained with commercially derived HA-
heparins of much lower Mr, that the upper limit for the
number of antithrombin-binding sites per chain in rat
skin heparin proteoglycans was probably five or six.
In order to determine the upper limit in binding-site
density and to establish that the variation in antithrombin
affinity of HA-chains is correlated with the number of
discrete antithrombin-binding sites on the rat skin
proteoglycan chains, chemical andphysicochemical analy-
ses were used to determine the number of antithrombin-
binding sites on the HA-chain fractions previously
isolated and assayed for anticoagulant activity by
Homer (1987).
MATERIALS AND METHODS
The methods of isolating HA-chain fractions from 35S-
labelled rat skin heparin proteoglycans have been
described previously in detail (Homer, 1987). HA-chains
were eluted from antithrombin-agarose with an NaCl
concentration gradient, recovered by precipitation with
ethanol and quantified by metachromasia with Azure A.
Their'specific anticoagulant activities (with respect to
thrombin neutralization) were determined with a chromo-
genic assay. The fractions analysed in the current work
are these same materials. To facilitate comparison with
the earlier work, the heparin fraction numbers assigned
previously (see the text and Fig. 5 of Homer, 1987)'have
been retained for this presentation.
HA-chain fractions were analysed by measuring the
heparin-induced enhancement in the intrinsic fluor-
escence of human antithrombin. The initial fluorescence
of a solution of antithrombin (O.17 /SM, 10,ug/ml, 1.7 ml
volume in 0.01 M-sodium phosphate buffer, pH 7.4) was
determined. Small portions of a solution of a heparin
fraction in the same buffer were then added successively
to this solution. After each addition fluorescence intensity
was measured, with correction mathematically for
dilution by the heparin titrant. Each heparin fraction was
added to antithrombin to a final concentration of at
least 7,UM, assuming an Mr of 80000 (Homer, 1987).
Fluorescence was measured on an SLM model SPF-
500C spectrofluorimeter, with an excitation wavelength
of 280 nm with a 1 nm slit width and an emission
wavelength of 314 nm with a 20 nm slit width. Stoichio-
metries were calculated from the fluorescence data, by
using a computerized non-linear least-squares fitting
routine, as described by Peterson & Blackbum (1985).
Antithrombin-binding regions were also determined
by analysis of the unique disaccharide marker sequence
glucuronosyl-N-sulphoglucosaminyl (3,6-di-O-sulphate),
which is confined exclusively to these regions in HA-
heparins (Lindahl et al., 1980; Thunberg et al., 1982;
Lindahl et al., 1984). The method has been fully described
by Jacobsson et al. (1986). HA-chain fractions were
deaminated with nitrous acid at pH 1.5 followed by
reduction with NaB3H4. The 3H-labelled disaccharides
were then fractionated by high-performance ion-
exchange chromatography on a column of Partisil-
IOSAX (Bienkowski & Conrad, 1985). Glucuronosyl-
[1-3H]anhydromannitol (3,6-di-O-sulphate) was obtained
as a minor but well-resolved component of the total
disaccharides. The number of binding sites per chain was
calculated by expressing this marker as a percentage of
the total disaccharides and assuming that the intact
chains and their constituent disaccharides had average
Mr values of 80000 and 600 respectively.
Abbreviations used: HA, high-affinity for antithrombin; LA, low affinity for antithrombin.
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Fig. 1. Enhancement of the intrinsic fluorescence of human
antithrombin by HA-heparin chain fractions
Experimental details are given in the Materials and
methods section. Fractions 28, 29, 30, 31, 32, 33 and 35
are represented by the symbols *, 0, *, A, *, El and
* respectively. The plot for fraction 34, which lay midway
between the plots of fractions 33 and 35, has been omitted.
In calculating antithrombin-binding-site densities from
these data an Mr value of 80000 has been assumed. This
value, previously used by Jacobsson et al. (1986) and
Horner (1987), is based on the ultracentrifugal analyses
made by Robinson et al. (1978).
RESULTS AND DISCUSSION
Rat skin heparin proteoglycan was treated with alkali,
and the released polysaccharide chains were fractionated
by affinity chromatography on antithrombin-agarose
(see the Materials and methods section and Horner,
1987). Individual fractions from the high-affinity portion
of the chromatogram (Fig. 2a) were tested for their
ability to enhance the fluorescence of human anti-
thrombin, an effect demonstrated by Einarsson &
Andersson (1977) and first used to determine the
stoichiometry of the interaction between antithrombin
and a high-affinity mucosal heparin preparation by
Nordenman et al. (1978). This readily measurable change
in fluorescence was used to generate saturation curves as
the protein was titrated with HA-heparin chains. The
change in protein fluorescence induced by the available
amounts of fractions 26 and 27 was too weak to generate
reliable data. Fig. 1 shows the fluorescence-enhancement
data for fractions 28-35. The antithrombin-binding site
densities calculated from these measurements are pre-
sented as histograms in Fig. 2(b). They range from 1.0
site per chain for fraction 28 to 4.8 sites per chain for
fractions 34 and 35. The mean binding-site density for
fractions 28-35 was 3.1 sites per chain.
The binding-site densities determined by direct chem-
ical analysis of fractions 28, 30, 32, 34 and 36 also are
presented as histograms in Fig. 2(b). They range from 0.4
site per chain for fraction 28 to 3.6 sites per chain for
fraction 36, with a mean value of 2.0 sites per chain. The
marker disaccharide could not be detected in fractions 26
and 27. If one estimates the binding-site densities of the
odd-numbered fractions, which were not analysed, by
making linear interpolations between the values for the
even-numbered fractions, the mean binding-site density
for fractions 28-36 is also 2.0 sites per chain. This value
is appreciably lower than the value of 2.8 sites per chain
reported by Jacobsson et al. (1986) for an HA-chain
preparation. A feasible explanation of the disparity is
that the latter value was for a selectively fractionated
preparation from the upper end of the range in affinity of
the total HA-proteoglycans, representing approx. 630
of the HA-chains derived from the total proteoglycan
starting material.
Antithrombin-binding-site densities calculated from
the physicochemical analyses were consistently higher
than those obtained by chemical analysis. Although
there is no obvious explanation for this discrepancy, it
may be due to selective loss of the marker disaccharide,
which was a minor proportion (0.3-2.7%) of the total
3H-labelled disaccharides, during the degradation pro-
cedures and multiple steps involved in the chemical
analyses. However, it is clear that the proportions of the
3H-labelled marker disaccharide essentially paralleled
the antithrombin-binding-site densities determined by
fluorescence enhancement.
It is reasonable to accept that the non-degradative
physicochemical analyses give quantitative data, since a
known amount of antithrombin is used in the fluor-
escence titration with known amounts of HA-chains.
Antithrombin binds in a 1:1 stoichiometric fashion with
antithrombin-binding sites in heparin (Jordan et al.,
1982; Nesheim et al., 1986), so that titration curves such
as those in Fig. 1, which are linear at low concentrations
of titrant and for which a saturating level of fluorescence
is measurable, can be easily extrapolated to determine
the molar concentration of antithrombin-binding sites
on a given heparin sample. The low-ionic-strength buffer
used in the fluorescence measurements ensured tight
binding of the ligand to the protein (Kd 10-8 M), so that
the titration curves shown were easily fitted by a non-
linear least-squares routine to determine the density of
antithrombin-binding sites for each HA-chain fraction.
These chains were found to contain from one to five
antithrombin-binding sites, with the predominant type
(fractions 30 and 31, Fig. 2a) having three sites per chain.
Fig. 2(b) also shows that the relationship between
antithrombin-binding-site density and anticoagulant
specific activity is approximately linear.
The analytical data confirm and extend the findings
and proposals made on the basis of anticoagulant assays
of the same HA-chain preparations by Horner (1987).
In the case of the fluorescence-enhancement data, an
interesting comparison can be made with results obtained
by the same procedure with HA-heparin fractions
prepared from commercial pig mucosal heparin by
Nesheim et al. (1986). They obtained six fractions with
Mr values ranging from 10000 to 30000 and observed a
linear increase in the number of antithrombin-binding
sites per molecule from 1.0 to 2.1. If their data are
extrapolated linearly, heparin with an Mr of 80000,
comparable with that of the HA-chains used in the
present study, would have 4.9 antithrombin-binding sites
per molecule. It thus appears that the upper limit of
binding-site density is essentially the same in heparins
from rat skin and pig intestinal mucosa.
Establishing the upper limit of antithrombin-binding-
site density allows us to elaborate on the findings of
Horner (1987) concerning the heterogeneity of HA-
proteoglycans and HA-chains. By fractionating HA-
proteoglycans and their constituent chains, it was
shown that the ratio of LA-chains to HA-chains in
1988
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Fig. 2. (a) Elution of HA-heparin chains from a column of antithrombin-agarose with an NaCl concentration gradient, and (b)
antithrombin-binding-site densities and anticoagulant specific activities of HA-heparin chain fractions 28-36
(a) Elution of HA-heparin chains from a column of antithrombin-agarose with an NaCl concentration gradient. *, Heparin
mass, expressed as a percentage of the total heparin in fractions 28-36, determined by metachromasia with Azure A after
recovering the heparin in each fraction by precipitation with ethanol; 0, NaCl concentration, determined by measuring
conductivity. The data, including the fraction numbers, are taken from Fig. 5 in the paper by Homer (1987). (b) Antithrombin-
binding-site densities and anticoagulant specific activities of HA-heparin chain fractions 28-36. O, Antithrombin-binding sites
per chain, determined from single chemical analyses for the disaccharide sequence glucuronosyl-N-sulphoglucosaminyl (3,6-di-
0-sulphate) (Jacobsson et al., 1986). U, Antithrombin-binding sites per chain, determined by fluorescence enhancement;
n = 1 for fraction 28; other values are means+S.D., n = 2 for fraction 29, n = 3 for fractions 31, 33, 34 and 35 and n = 4 for
fractions 30 and 32. *, Anti-(Factor Ila) activity, determined by amidolytic assay (Homer, 1987); values are means+S.D.,
n = 4.
A B C D E F
Fig. 3. Hypothetical heparin proteoglycan molecules, each comprised of 12 heparin chains attached to a polypeptide core, corresponding
to average M, values of 1 x 106 for rat skin heparin proteoglycans (Horner, 1971) and 8 x 104 for the chains (Robinson et al.,
1978)
The black circles represent antithrombin-binding sites, introduced sequentially into an LA-proteoglycan (A) to give HA-
proteoglycans containing chains with increasing antithrombin-binding-site densities, labelled B to F. (Intermediate species with
odd numbers of antithrombin-binding sites per proteoglycan molecule have been omitted.) This progressive sequence is
consistent with earlier data (Horner, 1987).
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HA-proteoglycans ranged from approx. 4: 1 to approx.
1:4 in six HA-proteoglycan subfractions. Furthermore,
as the proportions of HA-chains increased, so did their
degree of affinity for antithrombin, i.e. their binding-
site densities (see Table 1 and Figs. 3 and 4 in Homer,
1987).
These findings can be rationalized into the hypothetical
biosynthetic scheme presented in Fig. 3. The incor-
poration of the 3-0-sulphate group concludes the
formation of the antithrombin-binding site (Riesenfeld
etal., 1983; Kuscheetal., 1987). The scheme thus illustrates
how these sites are generated by progressive 3-0-
sulphation of glucosamine residues in a precursor
proteoglycan (model A). Limited interaction with the 3-
O-sulphotransferase would give products at the low end
of the HA-proteoglycan spectrum such as model B.
Extensive 3-0-sulphation would produce proteoglycans
in which some chains achieved maximal binding-site
density (model F). Introduction of antithrombin-binding
sites has been stopped at this stage, as even proteoglycans
of the highest affinity contain some LA-chains (Homer,
1987). The orderly distribution of sites is entirely
speculative.
There are two major possible explanations, not
necessarily mutually exclusive, for the asymmetric distri-
bution of antithrombin-binding sites in heparin proteo-
glycans. The first envisages limited access of poly-
saccharide chains to 3-0-sulphotransferase molecules.
Lindahl et al. (1986) presented a model of heparin
biosynthesis in mast cells in which the proteoglycan
traverses distinct groups of membrane-bound enzyme
complexes in the Golgi apparatus in an order that reflects
the sequence of post-polymerization modification reac-
tions. The authors suggested that a restricted distribution
within the membrane complex of the glucosaminyl 3-0-
sulphotransferase required for synthesis of antithrombin-
binding sites might explain the non-random distribution
of these sites in the final products. According to this
model, the results obtained by Jacobsson et al. (1986), by
Horner (1987) and in the present study would imply that
some heparin chains passing through the Golgi encounter
more 3-0-sulphotransferase enzyme 'stations' than
others, and furthermore that a majority of chains,
including in many cases all the chains comprising a
complete proteoglycan molecule, do not encounter the
3-0-sulphotransferase at all. If this proposal is valid,
variations in the number of glucosaminyl 3-0-sulpho-
transferase molecules at station III in different bio-
synthetic units (see Lindahl et al., 1986) could correlate
with variations in antithrombin-binding-site density.
The model as presented would produce HA-chains
that were uniform with respect to antithrombin-binding-
site density, in the proteoglycans formed by any one
biosynthetic unit, rather than products of the general
type shown in Fig. 3. However, for the sake of simplicity,
this model presented proteoglycans undergoing polymer
modification as being two-dimensional, which is not
necessarily the case. If the array of enzyme stations in a
biosynthetic unit in the Golgi apparatus is in fact a flat
bed of membrane-bound enzymes, traversed by a three-
dimensional proteoglycan molecule, it is easier to
envisage how different polysaccharide chains could
interact to differing degrees with glucosaminyl 3-0-
sulphotransferase molecules. Clearly all chains do inter-
act with the other sulphotransferases, which must be
much more abundant.
The other factor that may control antithrombin-
binding-site synthesis is the distribution along the
polysaccharide chains of recognition sites for the 3-0-
sulphotransferase. The studies cited above, showing that
3-0-sulphation concludes the formation of the aliti-
thrombin-binding region, also point to a stringent
substrate specificity for the 3-0-sulphotransferase: only
pentasaccharide sequences that express all the structural
features required for antithrombin binding except the 3-
0-sulphate group are recognized by the enzyme. Con-
ceivably, the key to the distribution of antithrombin-
binding sites lies in the distribution of these recognition
sites, synthesized during earlier stages of polymer
modification. Polysaccharide chains predestined to
remain LA-chains would lack these recognition sites and
would therefore not be attacked by the 3-0-sulpho-
transferase.
The elucidation of the precise regulatory mechanisms
involved in the synthesis of antithrombin-binding sites is
a challenge, considering the marked diversity of products
containing these sites. The current work and earlier
studies with rat skin heparin proteoglycans (Homer &
Young, 1982; Jacobsson et al., 1986; Homer, 1987)
illustrate the diversity of antithrombin-binding-site den-
sities in products from a single source. In such a case
structural differences may be related, for example, to
variations in degree of maturation of mast cells (Yong
et al., 1975). The extent of antithrombin-binding-
site synthesis also varies markedly in heparins in different
tissues of a single species (Homer, 1986), and in heparins
from different species (Hovingh et al., 1986). Heparan
sulphates also differ markedly in antithrombin-binding-
site density (Marcum et al., 1986; Hovingh et al., 1986;
Pejler et al., 1987). Addition of n-butyrate to cell cultures
stimulated the synthesis of binding sites in mastocytoma-
cell heparin (Jacobsson et al., 1985) and in endothelial-
cell heparan sulphate (Marcum et al., 1986). Thus
variations in antithrombin-binding-site density occur
naturally and can be induced pharmacologically. Such
changes are likely to regulate the expression of anti-
coagulant activity in endogenous heparins and heparan
sulphates. Their control therefore has important physio-
logical and pathological implications.
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